MAGEA3 and neoplasm: These immunotherapies are guided into the following fields: (1) monoclonal antibodies against either tumor cells (bevacizumab [81], cixutumumab [82], rituximab [83], etc.)or immunosuppressive factors (tremelimumab [84], nivolumab [85], etc.); (2) tumor vaccines based on polypeptide (MAGE-A3 [86], etc.), DCs (belagenpumatucel-L [87], etc.), or other targets vaccines; (3) immune cells adoptive treatment, such as CIK [88]; (4) soluble tumor virus gene therapy [89], such as GC0070 and GL-ONC1.